SG10201804330YA - Engineered high-affinity human t cell receptors - Google Patents

Engineered high-affinity human t cell receptors

Info

Publication number
SG10201804330YA
SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA
Authority
SG
Singapore
Prior art keywords
tcrs
cell receptors
affinity
affinity human
engineered
Prior art date
Application number
SG10201804330YA
Other languages
English (en)
Inventor
Sheena N Smith
Daniel T Harris
David M Kranz
Thomas M Schmitt
Philip D Greenberg
Original Assignee
Univ Illinois
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Hutchinson Fred Cancer Res filed Critical Univ Illinois
Publication of SG10201804330YA publication Critical patent/SG10201804330YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201804330YA 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors SG10201804330YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22

Publications (1)

Publication Number Publication Date
SG10201804330YA true SG10201804330YA (en) 2018-07-30

Family

ID=53180203

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804330YA SG10201804330YA (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors
SG10201804335QA SG10201804335QA (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201804335QA SG10201804335QA (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Country Status (20)

Country Link
US (4) US10023625B2 (https=)
EP (2) EP3071593B1 (https=)
JP (4) JP6476182B2 (https=)
KR (2) KR102415259B1 (https=)
CN (2) CN105873945B (https=)
AU (4) AU2014352826B2 (https=)
BR (1) BR112016011567A2 (https=)
CA (2) CA2930847A1 (https=)
DK (1) DK3071593T3 (https=)
ES (1) ES2729406T3 (https=)
IL (2) IL245467B (https=)
MX (3) MX383471B (https=)
PL (1) PL3071593T3 (https=)
PT (1) PT3071593T (https=)
RU (2) RU2729383C2 (https=)
SA (1) SA516371174B1 (https=)
SG (2) SG10201804330YA (https=)
TR (1) TR201908404T4 (https=)
WO (2) WO2015077615A1 (https=)
ZA (2) ZA201603116B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR102415259B1 (ko) 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
ES3063691T3 (en) * 2015-09-22 2026-04-20 Univ Wuerzburg J Maximilians A method for high level and stable gene transfer in lymphocytes
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
RU2019116312A (ru) 2016-11-14 2020-12-14 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性mage-a1特異的tcr及びその使用
JP7328211B2 (ja) * 2017-04-24 2023-08-16 オスペダーレ サン ラファエレ エス.アール.エル Tcr及びペプチド
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 T細胞レセプター
CN112739339B (zh) * 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
JP7737978B2 (ja) * 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Wt-1に特異的なt細胞免疫療法
AU2021218412A1 (en) * 2020-02-12 2022-09-08 Abbvie Inc. Bispecific binding molecules
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
US20240287456A1 (en) 2021-06-22 2024-08-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
US20250073333A1 (en) * 2021-07-19 2025-03-06 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
DE69936927T2 (de) 1998-10-21 2008-05-15 Altor Bioscience Corp., Miramar Polyspezifische bindemoleküle und deren verwendung
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
AU2005246073B2 (en) 2004-05-19 2010-10-28 Adaptimmune Limited Method of improving T cell receptors
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
DK2352756T3 (da) * 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2486049A1 (en) * 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
BR112013003647A2 (pt) * 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
KR102415259B1 (ko) 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技(上海)有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
JP2017501130A (ja) 2017-01-12
IL245468B (en) 2020-10-29
MX2016006625A (es) 2016-12-02
US20220396606A1 (en) 2022-12-15
SG10201804335QA (en) 2018-06-28
MX2021006932A (es) 2021-07-07
CN105899530B (zh) 2020-05-08
RU2740648C2 (ru) 2021-01-19
CN105873945B (zh) 2020-07-17
WO2015077607A1 (en) 2015-05-28
IL245467A0 (en) 2016-06-30
WO2015077615A1 (en) 2015-05-28
IL245468A0 (en) 2016-06-30
AU2019272003B2 (en) 2021-05-06
RU2016124179A (ru) 2017-12-27
SA516371174B1 (ar) 2019-04-14
CN105899530A (zh) 2016-08-24
RU2729383C2 (ru) 2020-08-06
RU2016124163A (ru) 2017-12-27
CA2930852A1 (en) 2015-05-28
US20160280755A1 (en) 2016-09-29
NZ719720A (en) 2020-09-25
JP2020007374A (ja) 2020-01-16
CA2930847A1 (en) 2015-05-28
CA2930852C (en) 2024-01-23
EP3071593B1 (en) 2019-03-13
BR112016011567A2 (pt) 2017-10-24
MX2016006620A (es) 2017-05-11
AU2014352834A1 (en) 2016-05-26
NZ719707A (en) 2020-09-25
US10344075B2 (en) 2019-07-09
MX383471B (es) 2025-03-14
ES2729406T3 (es) 2019-11-04
AU2014352826A1 (en) 2016-05-26
ZA201603116B (en) 2018-12-19
US20160280756A1 (en) 2016-09-29
JP6476182B2 (ja) 2019-02-27
JP6970724B2 (ja) 2021-11-24
JP2022023196A (ja) 2022-02-07
JP6697386B2 (ja) 2020-05-20
MX371202B (es) 2020-01-22
CN105873945A (zh) 2016-08-17
EP3071594A1 (en) 2016-09-28
US20190055298A1 (en) 2019-02-21
KR102415259B1 (ko) 2022-06-30
PL3071593T3 (pl) 2019-11-29
EP3071594A4 (en) 2017-05-03
AU2014352834B2 (en) 2019-08-29
KR20160087866A (ko) 2016-07-22
BR112016011583A2 (pt) 2017-09-26
AU2019272003A1 (en) 2019-12-19
EP3071593A1 (en) 2016-09-28
ZA201603169B (en) 2020-05-27
JP2017501129A (ja) 2017-01-12
AU2014352826B2 (en) 2019-08-01
TR201908404T4 (tr) 2019-07-22
AU2021202274A1 (en) 2021-05-06
DK3071593T3 (da) 2019-06-11
IL245467B (en) 2020-04-30
US10023625B2 (en) 2018-07-17
PT3071593T (pt) 2019-06-27
EP3071593A4 (en) 2017-05-03
KR20160085345A (ko) 2016-07-15

Similar Documents

Publication Publication Date Title
SG10201804330YA (en) Engineered high-affinity human t cell receptors
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
PH12019502529A1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
EP4279579A3 (en) Methods and compositions for natural killer cells
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
ZA201700872B (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
IN2014DN09787A (https=)
MX2015017036A (es) Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas.
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
WO2012021632A3 (en) Generation and use of pluripotent stem cells
MX2014014337A (es) Metodo de produccion de alta concentracion de celulas madre.
AU2016335217A8 (en) Antigen receptors and uses thereof
WO2014122035A3 (en) Induced dendritic cells and uses thereof
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도